RESEARCH ARTICLE

Detection of overdose and underdose prescriptions—An unsupervised machine learning approach

Kenichiro Nagata1,*, Toshikazu Tsuji1, Kimitaka Suetsugu1, Kayoko Muraoka1, Hiroyuki Watanabe2, Akiko Kanaya1, Nobuaki Egashira1, Ichiro Ieiri1

1 Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan, 2 Department of Pharmacy, Fukuoka Tokushukai Hospital, Fukuoka, Japan

* nagata.kenichiro.679@m.kyushu-u.ac.jp

Abstract

Overdose prescription errors sometimes cause serious life-threatening adverse drug events, while underdose errors lead to diminished therapeutic effects. Therefore, it is important to detect and prevent these errors. In the present study, we used the one-class support vector machine (OCSVM), one of the most common unsupervised machine learning algorithms for anomaly detection, to identify overdose and underdose prescriptions. We extracted prescription data from electronic health records in Kyushu University Hospital between January 1, 2014 and December 31, 2019. We constructed an OCSVM model for each of the 21 candidate drugs using three features: age, weight, and dose. Clinical overdose and underdose prescriptions, which were identified and rectified by pharmacists before administration, were collected. Synthetic overdose and underdose prescriptions were created using the maximum and minimum doses, defined by drug labels or the UpToDate database. We applied these prescription data to the OCSVM model and evaluated its detection performance. We also performed comparative analysis with other unsupervised outlier detection algorithms (local outlier factor, isolation forest, and robust covariance). Twenty-seven out of 31 clinical overdose and underdose prescriptions (87.1%) were detected as abnormal by the model. The constructed OCSVM models showed high performance for detecting synthetic overdose prescriptions (precision 0.986, recall 0.964, and F-measure 0.973) and synthetic underdose prescriptions (precision 0.980, recall 0.794, and F-measure 0.839). In comparative analysis, OCSVM showed the best performance. Our models detected the majority of clinical overdose and underdose prescriptions and demonstrated high performance in synthetic data analysis. OCSVM models, constructed using features such as age, weight, and dose, are useful for detecting overdose and underdose prescriptions.
Introduction

Prescription errors that occur in hospitals cause adverse drug events (ADEs), that may occasionally result in death [1]. In a recent systematic review, the frequency of prescription errors was at least 2%, while that of preventable ADEs was estimated to be 0.4% [2]. The World Health Organization has announced its global patient safety challenge, which aims to reduce medication-related harm by 50% within five years by improving unsafe practices and reducing medication errors [3]. Prescription errors related to drug overdose may result in serious life-threatening ADEs, while those related to the underdosing of drugs may lead to diminished therapeutic effects. Thus, it is particularly important to detect and prevent these errors before the administration of drugs [4, 5]. Previous studies suggested that the implementation of Electronic Health Records (EHRs) with Clinical Decision Support (CDS) systems is useful for detecting and preventing prescription errors, including overdoses and underdoses [6–13]. However, current CDS systems have two main limitations. The first issue is that most of these systems are rule-based and can thus only detect prescription errors according to pre-programmed rules. Moreover, in the case of insufficient information from reliable sources (e.g., a lack of pediatric dosage information in a drug label), difficulties are associated with making rules. The second issue is that current CDS systems may raise too many false-positive alerts, which result in medical staff habitually overriding them [14, 15]. This is called “alert fatigue.” Therefore, the development of more precise CDS systems is urgently needed [16–19]. To overcome these limitations, a non-rule-based novel approach is required.

In clinical practice, the majority of prescriptions are generally within the appropriate dose range, and overdose and underdose prescriptions are extremely rare [5]. Thus, the detection of abnormal prescriptions involves the identification of a small amount of abnormal data among mostly normal data. This issue has been examined as unsupervised anomaly detection in the field of machine learning [20].

Related works

To the best of our knowledge, MedAware (Raanana, Israel) is the first commercial system for preventing prescription errors by utilizing machine learning techniques [21]. This system enables the generation of automatic alerts by analyzing EHRs and detects overdose and underdose prescriptions with low false-positive rates [22–24]. Segal et al. introduced a machine learning based CDS system (MedAware) in clinical practice and evaluated its usefulness [23]. The system analyzed 78,017 prescriptions, generated 282 alerts (0.4%), and resulted in discontinuation or change in 135 prescriptions. However, this report does not provide information about the machine learning process, probably due to commercial reasons.

Santos et al. applied a graph centrality approach, known as density-distance-centrality (DDC), for outlier detection to identify overdose and underdose prescriptions [25]. They showed that DDC achieved better results than typical unsupervised machine learning techniques [25]. However, they only used two features, “dose” and “daily frequency,” and did not consider “age” and “weight,” which are critical factors for clinical dosage adjustments [25]. Recently, they developed a SaaS (software as a service) called NoHarm.ai which enables screening for non-standard prescriptions by analyzing hospital data [26].

Corny et al. proposed a hybrid CDS system based on a rule-based technique and supervised machine learning approach [27]. They combined patient-related data (e.g., age, weight, sex) and rule-based alerts (e.g., dosage, frequency, route) for each prescription with labeling (binary: 1 = a pharmaceutical intervention; 0 = no pharmaceutical intervention) and used it as training data. Using LightGBM, a gradient-boosting framework based on decision tree algorithms, predicted scores at the patient level were calculated. Their hybrid CDS system showed
higher performance than the classic CDS system (F-measure 0.74 vs. 0.61). However, in the clinical applicability of CDS systems, it is challenging to obtain precisely labeled data for a huge number of prescriptions. In addition, because their method starts from the rule-based technique, it requires pre-programmed rules. If it is difficult to make rules due to insufficient information (e.g., a lack of pediatric dosage information in a drug label), their system will not work. Unsupervised machine learning algorithms can be used to solve these problems.

As far as we know, there have been no further attempts to detect prescription errors of overdoses and underdoses using machine learning. In order to establish a method for detecting drug overdose and underdose using machine learning, open discussions with detailed explanations and analysis codes are necessary.

The purpose of this study was to detect extreme overdose and underdose prescriptions that occur very rarely in clinical practice using unsupervised machine learning algorithms. We constructed models for each candidate drug using three features: age, weight, and dose, and evaluated their usefulness for detecting overdose and underdose prescriptions.

Methods

This study was approved by the Ethics Committee of the Kyushu University Hospital (approval number 2020–187). All data were fully anonymized before access and the ethics committee waived the requirement for informed consent.

Investigation of clinical overdose and underdose prescriptions

Clinical overdose and underdose prescriptions, which were identified and rectified by pharmacists before dispensing in our hospital between January 1 and December 31, 2019, were collected. Thirty-one clinical overdose and underdose prescriptions (consisting of 21 drugs) that met the following conditions were analyzed:

- oral drugs
- more than 1000 in-hospital prescriptions between January 1, 2014 and December 31, 2019 (to ensure sufficient training data for the construction of the OCSVM model)
- based on drug labels or the UpToDate database [28], the maximum dose and minimum dose could be defined according to age, weight, or both (to create synthetic overdose and underdose prescriptions to evaluate OCSVM model performance)

Data preprocessing

We extracted prescription data and weight data from EHRs between January 1, 2014 and December 31, 2019. In terms of weight data, patients less than 0 kg or more than 300 kg were excluded because they were considered to be input errors. In prescription data, the dose was converted to the value corresponding to the amount of the active ingredient. Each set of prescription data was linked to the closest weight data, and data that met the following conditions were included in the analysis:

- prescriptions of 21 drugs (identified in the previous section)
- in-hospital prescriptions
- ordered in daily dose (prescription data entered by “single dose taken when needed” and “total dose” were excluded because the actual dose taken by patient was unknown)
OCSVM methodology

The OCSVM methodology was initially proposed by Schölkopf et al. [29] OCSVM requires the majority of training data to be normal, fits a hyperplane to include the majority of training data, and detects abnormal data as deviations from the decision boundary. First, the method maps the training data into the feature space corresponding to a simple kernel

\[ k(x_i, x_j) = \Phi(x_i) \cdot \Phi(x_j) \]  

(1)

such as the radial basis function (RBF) kernel

\[ k(x_i, x_j) = \exp\left(-\gamma||x_i - x_j||^2\right), \gamma > 0 \]  

(2)

where \( \gamma \) represents a kernel coefficient.

To separate the data from the origin, the following dual problem was solved

\[ \min_{\alpha} \frac{1}{2} \sum_{i,j} \alpha_i \alpha_j k(x_i, x_j) \]  

(3)

subject to

\[ 0 \leq \alpha_i \leq \frac{1}{m}, \sum \alpha_i = 1. \]  

(4)

Here, \( \alpha_i \) is a Lagrange multiplier, \( \nu \) defines the maximum fraction of outliers in training data, \( l \) is the number of points in the training dataset. The resulting decision function can be expressed as

\[ f(x) = \sum_i \alpha_i k(x_i, x) - \rho \]  

(5)

where the offset \( \rho \) can be obtained as

\[ \rho = \sum_i \alpha_i k(x_i, x). \]  

(6)

In OCSVM, we employed the implementation available in scikit-learn 0.22.1 [30]. We used the RBF as a kernel trick. The performance of OCSVM with the RBF kernel is strongly influenced by two hyperparameters: \( \nu \) and \( \gamma \). The incidence of clinical overdose and underdose prescriptions for each drug was between 0.01% and 0.44% (S1 Table). Therefore, we set the \( \nu \) value to 1% (0.01) in the present study. The hyperparameter \( \gamma \) affects the influence area of the support vectors on the classification. In general, increasing the value of \( \gamma \) implies adjusting the frontier closer to the training data and improving recall. However, a marked increase in \( \gamma \) causes overfitting of the model to the training data and deteriorates precision. The hyperparameter \( \gamma \) was set to “scale,” which is the default setting in scikit-learn 0.22.1, and calculated as follows:

\[ \gamma = \frac{1}{f \cdot v} \]  

(7)

where \( f \) is the number of features and \( v \) represents the variance in the dose of training data.

- weight data existed within 90 days before or after prescription
Experiment 1: Evaluation of OCSVM model performance for clinical overdose and underdose prescriptions

Age, weight, and daily dose were extracted as features from the prescription data between January 1, 2014 and December 31, 2019. We used these prescription data as training data and constructed an OCSVM model for each drug (total of 21 models). In each clinical overdose and underdose prescription (total of 31 prescriptions), age, weight, and daily dose were standardized by removing the mean and scaling to unit variance based on the training data using the StandardScaler module in scikit-learn and we applied it to the OCSVM model. The OCSVM model returned the signed distance to the separating hyperplane and predicted whether each prescription was normal (positive value, inside the decision boundary) or abnormal (negative value, outside the decision boundary).

Experiment 2: Evaluation of OCSVM model performance for synthetic overdose and underdose prescriptions

To ensure sufficient data for the evaluation of OCSVM model performance, we created synthetic overdose and underdose prescriptions and conducted a five-fold cross-validation analysis for each drug. The maximum dose and minimum dose according to age, weight, or both were defined based primarily on drug labels and secondarily on UpToDate (when there was insufficient information in the drug labels). The entire dataset (prescription data between January 1, 2014 and December 31, 2019) was randomly divided into five folds, and four folds of the dataset were used as training data. From one-fold of the dataset, we randomly selected 50% that were within the maximum and minimum doses and used them as normal prescriptions. Regarding the other 50% of the dataset, we artificially changed the daily dose to 2 times the maximum dose for synthetic overdose prescriptions and to 0.1 times the minimum dose for synthetic underdose prescriptions. Data (age, weight, and daily dose) on normal prescriptions and synthetic overdose and underdose prescriptions were standardized based on training data and applied to the OCSVM model of the corresponding drug. To evaluate OCSVM model performance, we used the following metrics:

- True positives (TP): the number of synthetic overdose or underdose prescriptions correctly predicted as abnormal
- False positives (FP): the number of normal prescriptions incorrectly predicted as abnormal
- True negatives (TN): the number of normal prescriptions correctly predicted as normal
- False negatives (FN): the number of synthetic overdose or underdose prescriptions incorrectly predicted as normal

\[
\text{Precision} = \frac{TP}{TP + FP} \quad (8)
\]
\[
\text{Recall} = \frac{TP}{TP + FN} \quad (9)
\]
\[
\text{F-measure} = \frac{2 \cdot \text{precision} \cdot \text{recall}}{(\text{precision} + \text{recall})} \quad (10)
\]

Random selection was repeated 10 times, and the average value was calculated to obtain robust results. The overall performance of OCSVM models was evaluated based on the average
of the metrics for 21 drugs. We changed the γ value logarithmically from $2^{-6}$ to $2^6$ and examined its influence on the OCSVM model performance.

To plot graphs, we used GraphPad Prism ver.8.4.1 for Windows (GraphPad Software, San Diego, CA, USA) for a line plot and Matplotlib 3.1.1, scikit-image 0.16.2, and MATLAB version 9.10.0.1602886 (The MathWorks Inc, Natick, MA, USA) for a three-dimensional plot [31, 32].

**Experiment 3: Comparative analysis with unsupervised outlier detection algorithms**

To compare model performance between OCSVM and other unsupervised outlier detection algorithms, we used the following methods.

- Local outlier factor (LOF): It measures the local density deviation of a given data point with respect to its neighbors [33]. The LOF score of an observation is equal to the ratio of the average local density of k-nearest neighbors and its own local density. It depends on hyperparameters: k (number of neighbors) and contamination (proportion of outliers in the data set).

- Isolation forest (ISO): It isolates observations by randomly selecting a feature and then randomly selecting a split value of the selected feature [34]. The number of splitting required to isolate a sample is equal to the path length from the root to the terminating node. This path length is a measure of normality and decision function. It depends on hyperparameters: estimators (number of base estimators in the ensemble) and contamination.

- Robust covariance (RC): Assuming gaussian distribution, it estimates the inlier location and covariance without being influenced by outliers [35]. The Mahalanobis distances obtained from this estimate are used to measure deviation. It depends on the hyperparameter of contamination.

We used synthetic overdose and underdose prescriptions created in Experiment 2 and conducted a five-fold cross-validation analysis using OCSVM, LOF, ISO and RC. We changed the value of hyperparameters as shown in Table 1, and the best F-measure was compared between algorithms.

**Results**

**Experiment 1: Evaluation of OCSVM model performance for clinical overdose and underdose prescriptions**

Details regarding the clinical overdose and underdose prescriptions that were prevented by pharmacists in 2019 are shown in Table 2. Thirty-one (20 overdose and 11 underdose)
prescriptions of 21 drugs were analyzed. To assess the degree of the deviation of clinical overdose and underdose prescriptions, the ratio to the maximum or minimum dose was calculated (Table 2). Regarding clinical overdose prescriptions, the median (range) of the ratio to the maximum dose was 1.88 (1.25–14.49). In the case of clinical underdose prescriptions, the median (range) of the ratio to the minimum dose was 0.13 (0.001–0.65). Twenty-seven out of 31 clinical overdose and underdose prescriptions (87.1%) were detected as abnormal by the OCSVM models.

Table 2. Details of clinical overdose and underdose prescriptions and detection results by OCSVM models.

| Drug name (strength)                  | Age | Weight (kg) | Dose (/day) | O/U | Ratio to max/min | OCSVM |
|---------------------------------------|-----|-------------|-------------|-----|-----------------|-------|
| Acetaminophen fine granule (500 mg/g) | 64  | 49.6        | 3 mg        | U   | 0.02            | +     |
|                                       | 68  | 51.1        | 3 mg        | U   | 0.02            | +     |
| Ambroxol hydrochloride dry syrup (15 mg/g) | 0   | 3.6         | 1.05 mg     | U   | 0.65            | -     |
|                                       | 0   | 2.6         | 8 mg        | O   | 1.71            | -     |
|                                       | 1   | 10.8        | 90 mg       | O   | 4.63            | +     |
| Amlodipine besylate tablet (5 mg/tablet) | 71  | 74.9        | 20 mg       | O   | 2.00            | +     |
| Aprepitant capsule (80 mg/capsule)    | 59  | 51.6        | 160 mg      | O   | 1.28            | +     |
| Aspirin tablet (100 mg/tablet)        | 81  | 43.0        | 10 000 mg   | O   | 2.33            | +     |
| Calcium carbonate tablet (500 mg/tablet) | 5   | 8.4         | 0.75 mg     | U   | 0.001           | +     |
| Carvedilol tablet (10 mg/tablet)      | 13  | 31.4        | 55 mg       | O   | 1.38            | +     |
|                                       | 70  | 55.8        | 200 mg      | O   | 5.00            | +     |
| Celecoxib tablet (200 mg/tablet)     | 54  | 59.1        | 800 mg      | O   | 1.33            | -     |
| Codeine phosphate powder (10 mg/g)    | 51  | 52.7        | 6 mg        | U   | 0.20            | +     |
|                                       | 69  | 61.2        | 6 mg        | U   | 0.20            | +     |
|                                       | 85  | 49.9        | 4 mg        | U   | 0.13            | +     |
| Furosemide fine granule (40 mg/g)     | 0   | 0.46        | 40 mg       | O   | 14.49           | +     |
|                                       | 13  | 30.0        | 0.25 mg     | U   | 0.02            | -     |
| Lactulose syrup (0.65 g/ml)           | 82  | 42.6        | 1.95 g      | U   | 0.20            | +     |
| Levothyroxine sodium hydrate tablet (25 μg/tablet) | 1   | 10.7        | 250 μg      | O   | 3.89            | +     |
| Nicorandil tablet (5 mg/tablet)       | 66  | 38.7        | 75 mg       | O   | 2.50            | +     |
| Nifedipine sustained release tablet (10 mg/tablet) | 47  | 69.5        | 140 mg      | O   | 1.75            | +     |
| Omeprazole tablet (10 mg/tablet)      | 4   | 10.9        | 20 mg       | O   | 2.00            | +     |
| Phenobarbital powder (100 mg/g)       | 66  | 53.8        | 500 mg      | O   | 1.25            | +     |
| Rabeprazole sodium tablet (10 mg/tablet) | 20  | 48.5        | 70 mg       | O   | 1.75            | +     |
|                                       | 58  | 74.8        | 70 mg       | O   | 1.75            | +     |
|                                       | 68  | 48.4        | 100 mg      | O   | 2.50            | +     |
| Rivaroxaban tablet (15 mg/tablet)     | 57  | 54.0        | 45 mg       | O   | 1.50            | +     |
| Spironolactone fine granule (100 mg/g) | 13  | 30.0        | 0.05 mg     | U   | 0.002           | +     |
|                                       | 74  | 47.5        | 500 mg      | O   | 2.50            | +     |
| Trimethoprim sulfamethoxazole granuled (80 mg/g) | 0   | 3.5         | 1.6 mg      | U   | 0.23            | +     |
| Ursodeoxycholic acid granule (50 mg/g) | 2   | 12.0        | 540 mg      | O   | 1.50            | +     |

a O, overdose; U, underdose.
b max, maximum dose; min, minimum dose defined by drug labels or UpToDate. The ratio to the maximum dose is shown for overdose. The ratio to the minimum dose is shown for underdose.
c “+” indicates detected, “-” indicates not detected as abnormal prescriptions, respectively.
d Dose is the value equivalent to trimethoprim.
Experiment 2: Evaluation of OCSVM model performance for synthetic overdose and underdose prescriptions

The performance of the OCSVM model for synthetic overdose and underdose prescriptions for each drug is shown in Table 3.

We plotted each prescription data and the decision boundary of the OCSVM model for acetaminophen fine granules in Fig 1. The results showed that the majority of normal prescriptions were inside the decision boundary, and all synthetic overdose prescriptions and most synthetic underdose prescriptions were outside the decision boundary.

The overall performance of the OCSVM models for synthetic overdose and underdose prescriptions is shown in Table 4.

The influences of the hyperparameter $\gamma$ on the OCSVM model performance for synthetic overdose and underdose prescriptions are shown in Fig 2A and 2B. Precision and recall were inversely related, that is, the smaller the $\gamma$ value, the higher the precision; and the larger the $\gamma$ value, the higher the recall.

Experiment 3: Comparative analysis with unsupervised outlier detection algorithms

The optimized hyperparameters and model performance of OCSVM, LOF, ISO and RC for synthetic overdose and underdose prescriptions are shown in Table 5.
Discussion

In our investigation of clinical overdose and underdose prescriptions, 12 out of 31 prescriptions were for children or infants, and 9 out of 21 drugs were in powder or liquid forms (Table 2). These results suggest that it is important to take “age” and “weight” into consideration when detecting overdose or underdose prescription errors that occur in clinical settings. In a previous study, in which the detection of overdose and underdose prescriptions was attempted using a graph centrality approach and typical unsupervised machine learning techniques, only “dose” and “daily frequency” were used as the features [25]. Although difficulties are generally associated with comparing the findings of the aforementioned study to the present results due to the use of different methods, their model showed lower performance (F-measure: 0.68) [25]. In the present study, we demonstrated for the first time that by using the three simple features of “age,” “weight,” and “dose,” OCSVM models detected the majority of

| Table 4. Overall performance of OCSVM models for synthetic overdose and underdose prescriptions. |
|------------------|--------------|----------|
|                   | Precision    | Recall   | F-measure |
| Synthetic overdose prescriptions | 0.986       | 0.964    | 0.973     |
| Synthetic underdose prescriptions   | 0.980       | 0.794    | 0.839     |

Data represent the average values of 21 drugs.
clinical overdose and underdose prescriptions (Table 2). Furthermore, the model demonstrated high performance in the synthetic data analysis (Table 4).

Difficulties are associated with obtaining sufficient clinical overdose and underdose prescription data to evaluate OCSVM model performance. Therefore, we defined maximum and minimum doses based on drug labels or UpToDate information and created synthetic overdose and underdose prescriptions. The factors of synthetic data (maximum dose × 2 or minimum dose × 0.1) were set according to the ratio of the clinical overdose to the maximum dose (median [range]: 1.88 [1.25–14.49]) or that of the clinical underdose to the minimum dose (0.13 [0.001–0.65]), as shown in Table 2, and were considered to be clinically feasible and of reasonable value.

In the analysis of OCSVM model performance (Table 3), all drugs showed high precision (> 0.94), which suggests that the low false-positive rate in our model avoided “alert fatigue.” Regarding synthetic overdose prescriptions, recall was > 0.82 for 20 out of 21 drugs and 0.703 for phenobarbital powder (Table 3). Among synthetic underdose prescriptions, recall was > 0.92 for 15 out of 21 drugs, but < 0.48 for six drugs, including phenobarbital powder.

Table 5. Comparative analysis with unsupervised anomaly detection algorithms.

| Algorithm     | Optimized hyperparameters | Precision | Recall | F-measure |
|---------------|----------------------------|-----------|--------|-----------|
| Synthetic overdose prescriptions | OCSVM | $\gamma = 2^{-1}, \nu = 2^{-6}$ | 0.980 | 0.969 | 0.973 |
|                | LOF | $k = 40, \text{contamination} = 2^{-5}$ | 0.968 | 0.932 | 0.942 |
|                | ISO | $\text{estimators} = 30, \text{contamination} = 2^{-4}$ | 0.897 | 0.746 | 0.784 |
|                | RC | $\text{contamination} = 2^{-4}$ | 0.874 | 0.763 | 0.781 |
| Synthetic underdose prescriptions | OCSVM | $\gamma = 2, \nu = 2^{-5}$ | 0.934 | 0.919 | 0.918 |
|                | LOF | $k = 60, \text{contamination} = 2^{-4}$ | 0.931 | 0.879 | 0.895 |
|                | ISO | $\text{estimators} = 20, \text{contamination} = 2^{-4}$ | 0.785 | 0.404 | 0.498 |
|                | RC | $\text{contamination} = 2^{-4}$ | 0.706 | 0.312 | 0.375 |

Data represent the average values of 21 drugs.

Fig 2. Influence of hyperparameter $\gamma$ on overall performance of OCSVM models. (A) Analysis for synthetic overdose prescriptions. (B) Analysis for synthetic underdose prescriptions.

https://doi.org/10.1371/journal.pone.0260315.g002
In our hospital, phenobarbital powder is often used in quantities outside the dose range described in the drug label or UpToDate, particularly when administered to infants and children (age: 0–5), with careful therapeutic drug monitoring being implemented before drug administration. In the prescription data for phenobarbital powder, 9.6% was above the maximum dose, while 3.9% was below the minimum dose (S2 Table), which may have resulted in low recall and F-measure values. These results indicate that because of its inherent nature, the machine learning approach may not have the capacity to detect prescriptions that are not rare, but that also require attention, such as the confirmation of blood concentrations. This issue may be resolved by adding drug blood concentrations to the features of the OCSVM model.

Regarding the overall performance of OCSVM models, excellent results were obtained for synthetic overdose prescriptions. However, the performance was slightly lower for synthetic undertose prescriptions (Table 4). Clinically, patients at a high risk of developing ADEs are sometimes administered drugs at lower doses than the minimum dose described in the drug label or UpToDate. Additionally, even if only one dose is prescribed for a drug that is administered multiple times daily (e.g., dosing only after dinner on the start date), our model recognized it as a daily dose. These factors may have limited the detection of synthetic undertose prescriptions.

\[ \gamma \]-dependent changes in the metrics are shown in Fig 2. F-measure peaked when \( \gamma = 2^{-1} \) for synthetic overdose prescriptions and \( 2^1 \) for synthetic undertose prescriptions. Therefore, setting \( \gamma \) approximately between 0.5 and 2.0 was considered to be appropriate. Moreover, adjustments of \( \gamma \) for each drug (high \( \gamma \) setting to prioritize recall for high-risk drugs, and low \( \gamma \) setting to prioritize precision for low-risk drugs) may enhance the utility in clinical settings.

In comparative analysis with unsupervised outlier detection algorithms, OCSVM showed the best F-measure for synthetic overdose and undertose prescriptions. Because LOF also showed high performance, OCSVM and LOF were considered as suitable algorithms for detecting overdose and undertose prescriptions.

This study considered age and weight, which are the main factors affecting dosage. Careful evaluation of several other factors related to the dose of individual drug, such as renal function (creatinine clearance), drug blood concentrations, and other laboratory parameters, may improve the model’s utility in further studies. To verify the results, we need to show that our model has high detection performance even for different data sets (e.g., prescription data obtained from other hospitals). The results of the present study may have implications for development of a CDS system based on our method in real clinical settings. In future studies, the efficacy of the system should be evaluated for its utility in alerting medical staff and subsequent benefits in treatment, in comparison with the current rule-based systems.

Conclusions

In the present study, we revealed that OCSVM models, constructed using three features: age, weight, and dose, detected the majority of clinical overdose and undertose prescriptions. Moreover, the models demonstrated high performance in the synthetic data analysis. These results suggest that our model is a useful CDS system for detecting prescription errors related to overdoses and undertoses. Further prospective studies are needed to assess the performance of the OCSVM model in real-world settings.

Supporting information

S1 Table. Occurrence rates of clinical overdose and undertose prescriptions for each drug. (DOCX)
S2 Table. Details of prescription data for phenobarbital powder.

(DOCX)

S1 File. Data and analysis code.

(ZIP)

Author Contributions

Conceptualization: Kenichiro Nagata.

Data curation: Kenichiro Nagata.

Formal analysis: Kenichiro Nagata.

Funding acquisition: Kenichiro Nagata.

Investigation: Kenichiro Nagata.

Methodology: Kenichiro Nagata, Toshikazu Tsuji, Kayoko Muraoka, Ichiro Ieiri.

Project administration: Kenichiro Nagata.

Validation: Kenichiro Nagata, Toshikazu Tsuji, Kimitaka Suetsugu, Kayoko Muraoka, Nobuaki Egashira, Ichiro Ieiri.

Visualization: Kenichiro Nagata.

Writing – original draft: Kenichiro Nagata.

Writing – review & editing: Kenichiro Nagata, Toshikazu Tsuji, Kimitaka Suetsugu, Kayoko Muraoka, Hiroyuki Watanabe, Akiko Kanaya, Nobuaki Egashira, Ichiro Ieiri.

References

1. Kohn LT, Corrigan JM, Donaldson MS. Committee on Quality of Health Care in America, Institute of Medicine. To Err is Human: Building a Safer Health System. Washington, DC: National Academy of Sciences; 2000.

2. Assiri GA, Shebl NA, Mahmoud MA, Aloudah N, Grant E, Aljadhey H, et al. What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature. BMJ Open. 2018; 8(5):e019101. https://doi.org/10.1136/bmjopen-2017-019101 PMID: 29730617

3. Sheikh A, Dhingra-Kumar N, Kelley E, Kierny MP, Donaldson LJ. The third global patient safety challenge: tackling medication-related harm. Bull World Health Organ. 2017; 95(8):546–546A. https://doi.org/10.2471/BLT.17.198002 PMID: 28804162

4. Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003; 60(17):1750–1759. https://doi.org/10.1093/ajhp/60.17.1750 PMID: 14503111

5. Kirkendall ES, Kouril M, Minich T, Spooner SA. Analysis of electronic medication orders with large overdoses. Appl Clin Inform. 2014; 5(1):25–45. https://doi.org/10.4338/ACI-2013-08-RA-0057 PMID: 24734122

6. Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998; 280(15):1311–1316. https://doi.org/10.1001/jama.280.15.1311 PMID: 9794308

7. Garg AX, Adhikari NKJ, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, et al. Effects of computerized clinical decision support systems on practitioner and patient outcomes. JAMA. 2005; 293:1223–1238. https://doi.org/10.1001/jama.293.10.1223 PMID: 15755945

8. Kuperman GJ, Bobb A, Payne TH, Avery AJ, Gandhi TK, Burns G, et al. Medication-related clinical decision support in computerized provider order entry systems: a review. J Am Med Inform Assoc. 2007; 14(1):29–40. https://doi.org/10.1197/jamia.M2170 PMID: 17068355
9. Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma’Luf N, et al. The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc. 1999; 6(4):313–321. https://doi.org/10.1136/jamia.1999.00660313 PMID: 10428004

10. Kuperman GJ, Teich JM, Gandhi TK, Bates DW. Patient safety and computerized medication ordering at Brigham and Women’s Hospital. Jt Comm J Qual Improv. 2001; 27(10):509–521. https://doi.org/10.1016/s1070-3241(01)27045-x PMID: 11593885

11. Page N, Baysari MT, Westbrook JI. A systematic review of the effectiveness of interruptive medication prescribing alerts in hospital CPOE systems to change prescriber behavior and improve patient safety. Int J Med Inform. 2017; 105:22–30. https://doi.org/10.1016/j.ijmedinf.2017.05.011 PMID: 28750908

12. Woods AD, Mulherin DP, Flynn AJ, Stevenson JG, Zimmerman CR, Chaffee BW. Clinical decision support for atypical orders: detection and warning of atypical medication orders submitted to a computerized provider order entry system. J Am Med Inform Assoc. 2014; 21(3):569–573. https://doi.org/10.1136/ami ajnl-2013-002008 PMID: 24253195

13. Lee J, Han H, Ock M, Lee S, Jo MW. Impact of a clinical decision support system for high-alert medications on the prevention of prescription errors. Int J Med Inform. 2014; 83(12):929–940. https://doi.org/10.1016/j.ijmedinf.2014.08.006 PMID: 25256067

14. Nanji KC, Seger DL, Slight SP, Amato MG, Beeler PE, Her QL, et al. Medication-related clinical decision support alert overrides in inpatients. J Am Med Inform Assoc. 2018; 25(5):476–481. https://doi.org/10.1093/jamia/ocx115 PMID: 29092059

15. van der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc. 2006; 13(12):138–147. https://doi.org/10.1197/jamia.M1809 PMID: 16357358

16. Cash JJ. Alert fatigue. Am J Health Syst Pharm. 2009; 66(23):2098–2101. https://doi.org/10.2146/ajhp090181 PMID: 19923309

17. Kesselheim AS, Cresswell K, Phansalkar S, Bates DW, Sheikh A. Clinical decision support systems could be modified to reduce ‘alert fatigue’ while still minimizing the risk of litigation. Health Aff (Millwood). 2011; 30(12):2310–2317. https://doi.org/10.1377/hlthaff.2010.1111 PMID: 22147858

18. Phansalkar S, van der Sijs H, Tucker AD, Desai AA, Bell DS, Teich JM, et al. Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. J Am Med Inform Assoc. 2013; 20(3):489–493. https://doi.org/10.1136/amiajnl-2012-001089 PMID: 23011124

19. Carroll AE. Averting alert fatigue to prevent adverse drug reactions. JAMA. 2019; 322(7):601. https://doi.org/10.1001/jama.2019.1171 PMID: 31429887

20. Goldstein M, Uchida S. A comparative evaluation of unsupervised anomaly detection algorithms for multivariate data. PLoS One. 2016; 11(4):e0152173. https://doi.org/10.1371/journal.pone.0152173 PMID: 27093601

21. MedAware. https://www.medaware.com/ (Accessed on May 13 2021)

22. Schiff GD, Volk LA, Volodarskaya M, Williams DH, Walsh L, Myers SG, et al. Screening for medication errors using an outlier detection system. J Am Med Inform Assoc. 2017; 24(2):281–287. https://doi.org/10.1093/jamia/ocw171 PMID: 28104826

23. Segal G, Segev A, Brom A, Lifshitz Y, Wasserstrum Y, Zimlichman E. Reducing drug prescription errors and adverse drug events by application of a probabilistic, machine-learning based clinical decision support system in an inpatient setting. J Am Med Inform Assoc. 2019; 26(12):1560–1565. https://doi.org/10.1093/jamia/ocz135 PMID: 31390471

24. Rozenblum R, Rodriguez-Monguio R, Volk LA, Forsythe KJ, Myers S, McGurin M, et al. Using a machine learning system to identify and prevent medication prescribing errors: a clinical and cost analysis evaluation. Jt Comm J Qual Patient Saf. 2020; 46(1):3–10. https://doi.org/10.1016/j.jcjq.2019.09.008 PMID: 31786147

25. Santos HDPD, Ulbrich AHDPS, Woloszyn V, Vieira R. DDC-Outlier: Preventing medication errors using unsupervised learning. IEEE J Biomed Health Inform. 2019; 23(2):874–881. https://doi.org/10.1109/JBHI.2018.2828026 PMID: 29993649

26. NoHarm.ai. https://noharm.ai (Accessed on Oct 27 2021)

27. Corny J, Rajkumar A, Martin O, Dode X, Lajonchere JP, Billuart O, et al. A machine learning-based clinical decision support system to identify prescriptions with a high risk of medication error. J Am Med Inform Assoc. 2020; 27(11):1688–1694. Epub 2020/09/29. https://doi.org/10.1093/jamia/ocaa154 PMID: 32984901

28. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (Accessed on May 13 2021)

29. Schölkopf B, Platt JC, Shawe-Taylor J, Smola AJ, Williamson RC. Estimating the support of a high-dimensional distribution. Neural Comput. 2001; 13(7):1443–1471. https://doi.org/10.1162/089976601750264965 PMID: 11440593
30. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in Python. J Mach Learn Res. 2011; 12:2825–2830.

31. Hunter JD. Matplotlib: A 2D graphics environment. Comput Sci Eng. 2007; 9(3):90–95. https://doi.org/10.1109/mcse.2007.55

32. Van Der Walt S, Schönberger JL, Nunez-Iglesias J, Boulogne F, Warner JD, Yager N, et al. Scikit-image: image processing in Python. PeerJ. 2014; 2:e453. https://doi.org/10.7717/peerj.453 PMID: 25024921

33. Breunig MM, Kriegel HP, Ng RT, Sander J. LOF: Identifying density-based local outliers. Sigmod Record. 2000; 29(2):93–104. https://doi.org/10.1145/335191.335388

34. Liu FT, Ting KM, Zhou ZH. Isolation-based anomaly detection. ACM Trans Knowl Discov Data. 2012; 6(1). https://doi.org/10.1145/2133360.2133363

35. Rousseeuw PJ, Van Driessen K. A fast algorithm for the minimum covariance determinant estimator. Technometrics. 1999; 41(3):212–223. https://doi.org/10.2307/1270566